Selective internal radiation therapy (SIRT) (radioembolisation (RE))

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-033802-2022-05-25T14:26:35+01:00",
    "date": "2022-05-25T14:26:35+01:00",
    "ocid": "ocds-h6vhtk-033802",
    "initiationType": "tender",
    "tender": {
        "id": "52433",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Selective internal radiation therapy (SIRT) (radioembolisation (RE))",
        "status": "planned",
        "classification": {
            "scheme": "CPV",
            "id": "85000000",
            "description": "Health and social work services"
        },
        "mainProcurementCategory": "services",
        "description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), is inviting suitably qualified and experienced suppliers to respond to this Market Engagement exercise relating to the delivery of Selective internal radiation therapy (SIRT), which may also be called radioembolisation (RE), as an option for treating unresectable advanced HCC in adults. NICE Technology Appraisal 688, (SIRT), approves the use of SIRT (both SIR-Spheres and TheraSpheres products) as an option for treating unresectable advanced HCC in adults, only if the products are: * used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies (transarterial embolisation and transarterial chemoembolisation) are inappropriate; and * the company provides SIR Spheres according to the commercial arrangement. NICE estimated that demand for this treatment will ramp-up over the next two years, reaching a steady state of around 340 patients by 2023/24, from a base of 80 in 2021-22. Reimbursement will be in 4 parts: * The work up procedure which groups to the core HRG YR54: Percutaneous Transluminal Embolisation of Peripheral Blood Vessel (1 per patient) * The treatment procedure which groups to the HRG YR57Z: Percutaneous, Chemoembolisation or Radioembolisation, of Lesion of Liver (estimated to be an average of c1.62 treatments per patient) * Unbundled radiotherapy SC28Z: Deliver a Fraction of Interstitial Radiotherapy (1 per treatment) * The cost of the microspheres (1 per treatment) The first 3 parts will be added to the fixed and variable elements of the 2022/23 Aligned Payment and Incentive agreements with NHS England Specialised Commissioning. The microspheres can be ordered through NHS Supply Chain as part of NHS England's Specialised Commissioning central procurement route and will be reimbursed via the Visible Cost Model (VCM) which is used for excluded device reimbursement. The estimated value for this contract is PS26.7m* over 3 years *based on list price of microspheres.",
        "value": {
            "amount": 26700000,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "1",
                "description": "Requirements Providers should be both a specialist liver centre and co-located (within the same city/town) with a radiotherapy service. A multidisciplinary team (MDT) approach must be in place to ensure appropriate patient selection and treatment; * Discussion and agreement to proceed at a specialist hepatobiliary multidisciplinary team (MDT) meeting * The specialised MDT must meet the Peer Review cancer standards and offer the full range of liver-directed treatment options for the indications agreed, offering genuine choice between clinically suitable options all cases must be discussed at an appropriate MDT with liver surgery representation; * Centres should have a minimum of two interventional radiology operators and a minimum of two Administration of Radioactive Substances Advisory Committee (ARSAC) licence holders for SIRT; * Centres should have adequate MDT, radio-pharmacy and Interventional Radiology capacity to support 10-20 cases per annum; * Procedures should be performed in an interventional radiology suite that is equipped with cone-beam CT; * There should be a SIRT nurse co-ordinator to provide individual expert advice and support for the whole SIRT patient pathway; and * Provide detailed radiation protection advice to patients and their partners. Governance Arrangements: Compliance with the Ionising Radiation (Medical Exposure) Regulations (IR(ME)R) 2017. It is mandatory that SIRT practitioners are able to demonstrate the completion and maintenance of suitable training and experience in SIRT. Interested parties are encouraged to register their interest and participate in the market questionnaire which will provide feedback to commissioners. Please note that this is not a call for competition although the commissioner would encourage all potential providers to respond to this market engagement exercise. It is possible that, as a result of this exercise, a formal tender process may not be required but instead a simpler supplier selection process may be considered. The outcome of this market engagement will help inform commissioners of the current and future capacity and capability of the market and will be considered with other evidence to inform the commissioning approach. The market engagement includes a clear outline of the service requirements in a questionnaire for potential providers to respond to, including the key requirements to ascertain the capability of providers. The anticipated contract duration for this service will be 3 years with an option to extend the contract by a further 12 month period, at the Commissioner's discretion. To respond to the market engagement exercise please follow this link https://uk.eu-supply.com/ctm/supplier/publictenders?B=UK The project reference is 52433 and the closing date for submission of the completed questionnaire is: 12 noon on 14th June 2022.",
                "status": "planned"
            }
        ],
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "85000000",
                        "description": "Health and social work services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "communication": {
            "futureNoticeDate": "2022-08-01T00:00:00+01:00"
        },
        "coveredBy": [
            "GPA"
        ],
        "amendments": [
            {
                "id": "1",
                "unstructuredChanges": [
                    {
                        "oldValue": {
                            "text": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), is inviting suitably qualified and experienced suppliers to respond to this Market Engagement exercise relating to the delivery of Selective internal radiation therapy (SIRT), which may also be called radioembolisation (RE), as an option for treating unresectable advanced HCC in adults. NICE Technology Appraisal 688, (SIRT), approves the use of SIRT (both SIR-Spheres and TheraSpheres products) as an option for treating unresectable advanced HCC in adults, only if the products are: * used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies (transarterial embolisation and transarterial chemoembolisation) are inappropriate; and * the company provides SIR Spheres according to the commercial arrangement. NICE estimated that demand for this treatment will ramp-up over the next two years, reaching a steady state of around 340 patients by 2023/24, from a base of 80 in 2021-22. Reimbursement will be in 4 parts: * The work up procedure which groups to the core HRG YR54: Percutaneous Transluminal Embolisation of Peripheral Blood Vessel (1 per patient) * The treatment procedure which groups to the HRG YR57Z: Percutaneous, Chemoembolisation or Radioembolisation, of Lesion of Liver (estimated to be an average of c1.62 treatments per patient) * Unbundled radiotherapy SC28Z: Deliver a Fraction of Interstitial Radiotherapy (1 per treatment) * The cost of the microspheres (1 per treatment) The first 3 parts will be added to the fixed and variable elements of the 2022/23 Aligned Payment and Incentive agreements with NHS England Specialised Commissioning. The microspheres can be ordered through NHS Supply Chain as part of NHS England's Specialised Commissioning central procurement route and will be reimbursed via the Visible Cost Model (VCM) which is used for excluded device reimbursement. The estimated value for this contract is PS26.7m* over 3 years *based on list price of microspheres."
                        },
                        "newValue": {
                            "text": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), is inviting suitably qualified and experienced suppliers to respond to this Market Engagement exercise relating to the delivery of Selective internal radiation therapy (SIRT), which may also be called radioembolisation (RE), as an option for treating unresectable advanced HCC in adults. NICE Technology Appraisal 688, (SIRT), approves the use of SIRT (both SIR-Spheres and TheraSpheres products) as an option for treating unresectable advanced HCC in adults, only if the products are: * used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies (transarterial embolisation and transarterial chemoembolisation) are inappropriate; and * the company provides SIR Spheres according to the commercial arrangement. * Please refer to the NICE guidance for: Selective internal radiation therapies for treating hepatocellular carcinoma. Technology appraisal guidance [TA688] Published: 31 March 2021. In summary, the guidance states: SIR-Spheres and TheraSphere, but not QuiremSpheres, are recommended for treating HCC Link to NICE guidance: https://www.nice.org.uk/guidance/ta688 Hence, QuiremSpheres should not be made available to order via NHS Supply Chain and will not be reimbursed via pass through. NICE estimated that demand for this treatment will ramp-up over the next two years, reaching a steady state of around 340 patients by 2023/24, from a base of 80 in 2021-22. Reimbursement will be in 4 parts: * The work up procedure which groups to the core HRG YR54: Percutaneous Transluminal Embolisation of Peripheral Blood Vessel (1 per patient) * The treatment procedure which groups to the HRG YR57Z: Percutaneous, Chemoembolisation or Radioembolisation, of Lesion of Liver (estimated to be an average of c1.62 treatments per patient) * Unbundled radiotherapy SC28Z: Deliver a Fraction of Interstitial Radiotherapy (1 per treatment) * The cost of the microspheres (1 per treatment) The first 3 parts will be added to the fixed and variable elements of the 2022/23 Aligned Payment and Incentive agreements with NHS England Specialised Commissioning. The microspheres can be ordered through NHS Supply Chain as part of NHS England's Specialised Commissioning central procurement route and will be reimbursed via the Visible Cost Model (VCM) which is used for excluded device reimbursement. The estimated value for this contract is PS26.7m* over 3 years"
                        },
                        "where": {
                            "section": "II.1.4"
                        }
                    }
                ]
            }
        ]
    },
    "parties": [
        {
            "id": "GB-FTS-49766",
            "name": "NHS England - Specialised Commissioning",
            "identifier": {
                "legalName": "NHS England - Specialised Commissioning"
            },
            "address": {
                "streetAddress": "80 London",
                "locality": "London",
                "region": "UK",
                "postalCode": "SE1 6LH",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Josselin Canevet",
                "telephone": "+44 1332888080",
                "email": "josselin.canevet@nhs.net",
                "url": "https://uk.eu-supply.com/ctm/supplier/publictenders?B=UK"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.england.nhs.uk/commissioning/spec-services/",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "NATIONAL_AGENCY",
                        "description": "National or federal agency/office"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "07",
                        "description": "Health"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-49766",
        "name": "NHS England - Specialised Commissioning"
    },
    "language": "en"
}